Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Novo Nordisk, Mylan
Novo Nordisk settles US patent fight with Viatris over Ozempic, Wegovy
Novo Nordisk and Viatris have agreed to resolve a patent dispute over Novo's blockbuster weight-loss drugs Ozempic and Wegovy, the companies told a U.S. Patent and Trademark Office tribunal.
Amid GLP-1 craze, Novo and Mylan ink patent settlement in Ozempic case
With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their generic to Novo Nordisk's wildly popular type 2 diabetes drug Ozempic. | Mylan Pharmaceuticals and Novo Nordisk have reached a confidential settlement in a patent lawsuit tied to generic Ozempic,
Mylan settles patent litigation with Novo Nordisk over generic Ozempic in United States
“Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the US patent litigation related to generic Ozempic (Semaglutide),” NATCO said in the filing. The terms of the settlement are confidential, it added.
Mylan and Novo Nordisk settle US generic Ozempic dispute, Natco Pharma poised for market entry
Mylan and Novo Nordisk have reached a confidential settlement over the generic version of Ozempic, with Natco Pharma holding Sole First-to-File (FTF) status for multiple strengths of Ozempic and Wegovy.
Settlement Reached in Ozempic Patent Battle
NATCO Pharma Ltd announced that Mylan Pharmaceuticals Inc has settled a lawsuit with Novo Nordisk in the US concerning the generic version of Ozempic—a medication used for controlling blood sugar and weight loss.
Natco Pharma soars after Mylan settles Ozempic patent dispute
Natco Pharma rose 3.39% to Rs 1400.60 after the company announced a settlement in the U.S. patent litigation for generic Ozempic.
Natco shares gain after antidiabetic drug partner Mylan, Novo Nordisk settle patent litigation
Natco Pharma shares rise 3% as partner Mylan settles U.S. patent litigation with Novo Nordisk for generic Ozempic.
Natco Pharma partner Mylan settles patent litigation with Novo Nordisk over generic Ozempic in US
Hyderabad: NATCO Pharma Limited has announced that its partner Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement of the U.S. patent litigation related to generic
Mylan Settles Patent Suit with Novo Nordisk over Generic Ozempic
Mylan Pharmaceuticals Inc. and Novo Nordisk have reached a settlement in the US over a patent infringement lawsuit regarding generic Ozempic, a drug used for blood sugar and weight loss.
Novo Nordisk (NYSE:NVO) and Viatris Settle Patent Dispute for Weight-Loss Drugs
Novo Nordisk ($NVO) and Viatris ($VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic and Wegovy, according
Novo Nordisk, Viatris settle patent dispute over Ozempic, Wegovy: report
Novo Nordisk (NVO) and Viatris (NASDAQ:VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo’s popular weight-loss drugs Wegovy and Ozempic. The companies announced the settlement in a joint filing on Friday made with the U.
FiercePharma
17h
Kaléo unveils 58 layoffs days after pledging to double in-office commercial team for EpiPen rival Auvi-Q
After Kaléo unveiled a “redesign” of the in-office commercial team for its EpiPen rival Auvi-Q at the start of the month, the ...
6d
Ex-Mylan executive gets prison time in $8M insider trading scheme
A former Mylan executive who pleaded guilty to insider trading in the pharmaceutical company’s stock will serve two years in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Related topics
Ozempic
Novo Nordisk
United States
Natco Pharma
Feedback